Navigation Links
InterMune Reports First Quarter 2013 Financial Results and Business Highlights
Date:4/24/2013

not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2013 (the "Form 10-K") and other periodic reports filed with the SEC, including but not limited to the following: (i) the risks related to the uncertain, lengthy and expensive clinical development process for the company's product candidates, including having no unexpected safety, toxicology, clinical or other issues and having no unexpected clinical trial results such as unexpected new clinical data and unexpected additional analysis of existing clinical data; (ii) risks related to the regulatory process for the company's product candidates, including the possibility that the results of the new 52-week Phase 3 clinical trial (ASCEND) having an FVC endpoint may not be satisfactory to the FDA for InterMune to receive regulatory approval for pirfenidone in the United States; (iii) risks related to unexpected regulatory actions or delays or government regulation generally; (iv) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue; (v) government, industry and general public pricing pressures; (vi) risks related to our ability to successfully launch and commercialize Esbriet in Europe and Canada, including successfully establishing a commercial operation in Europe and Canada and receiving favorable governmental pricing and reimbursement approvals in the various European countries and securing coverage from private insurance plans and reimbursement from public (provincial) drug reimbursement plans in Canada; and (vii) InterMune's ability to obtain or maintain patent or other proprietary intellectual property protections.  The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other fa
'/>"/>
SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
8. InterMune To Release First Quarter Financial Results On April 24
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
(Date:8/28/2014)... Sterlitech is proud to announce that it ... stable of products . These additional products increase ... membrane filters with surface charges. , “We ... our membrane process testing equipment, and correspondingly, a wider ... explains Sterlitech President Mark Spatz. “The addition of ...
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ... developing novel mid- to late-stage cardiovascular drug candidates, ... in its first round of financing. The Series ... and Hercules Bioventures with participation from investors that ... pharmaceutical executive, Dr. Larry Hsu , the ...
(Date:8/28/2014)... a Florida State University research team has led to ... emit white light, and convert photon energy directly to ... butterfly. , Biwu Ma, associate professor in the Department ... of Engineering, created the molecule in a lab about ... his creation has many other unique capabilities. , For ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2
... Chicago The global biotechnology industry will face ... ethical and regulatory fights to the rigors of engineering ... will compare with what immediately confronts the 20,000 convention ... can you really believe? , ,A walk-through in ...
... been a center for innovation and discovery. From medicine ... were made right here in our state. Today, amid ... taken the lead. , ,From developing innovative new ... relieve its dependence on foreign oil to working to ...
... The biotechnology industry has a job to do, former ... by thousands at the BIO Chicago conference. , ,He called ... guard against pandemics, create crops that can feed more of ... ethanol, and confront global warming head on. , ,Clinton's vision ...
Cached Biology Technology:My-oh, it's BIO! Where sales hype and science collide 2Making Wisconsin the biotechnology leader 2Making Wisconsin the biotechnology leader 3Clinton says world needs biofuels, GM crops, and more answers 2Clinton says world needs biofuels, GM crops, and more answers 3
(Date:8/28/2014)... of the world,s most important crop-producing countries will be ... century if current trends continue, according to a new ... than one-in-ten pest types can already be found in ... If this spread advances at its current rate, scientists ... will be overwhelmed by pests within the next 30 ...
(Date:8/27/2014)... single fungal cell or bacterial colony exerts on a plant ... role in setting up some of the most fundamental symbiotic ... much of a stretch to say that plants may have ... the touch of beneficial fungi, according to a new study ... University of Wisconsin-Madison. , "Many people have studied how ...
(Date:8/27/2014)... , Aug. 27, 2014  WaferGen Bio-systems, Inc. (NASDAQ: ... announced underwritten public offering of units of common stock ... for gross proceeds of $20 million, prior to deducting ... the Company.  The shares and warrants are immediately separable ... unit sold in the offering consists of 2,000 shares ...
Breaking Biology News(10 mins):New study charts the global invasion of crop pests 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3
... Muenchen (TUM) have been awarded prestigious ERC Grants: ... the development of drugs to combat multi-resistant germs; Prof. ... cellular components; 1.6 million goes to Prof. Andrzej Buras, ... particles; Prof. Daniel Cremers (1.98 million) is working on ...
... makers, industry, researchers and the public have a new ... the Bioenergy Knowledge Discovery Framework, or KDF, developed by ... by the Department of Energy. The new site ... from reports, technical data and a list of experts ...
... An international group of stem cell scientists, bioethicists ... today for specific measures designed to counter secrecy and ... of data, materials and collective management of intellectual property ... the Hinxton Groupso named for the British city where ...
Cached Biology News:Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 2Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 3Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 4Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 5Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 6New DOE bioenergy website has ORNL roots 2Recommendations issued to counter patent, proprietary barriers to sharing stem cell data 2Recommendations issued to counter patent, proprietary barriers to sharing stem cell data 3
... developed to significantly increase the shelf life ... is increased at room temperature storage conditions ... product is subjected to 0.45 micron filtration, ... This formulation insures consistently high levels of ...
... utilizies CTI Molecular Imaging's proprietary Focus™ ... sensitivty, and a large imaging volume ... to image multiple mice or large ... a dedicated small animal PET (Positron ...
... This product has been developed to ... peroxidase labeled proteins. Stability is increased ... to 2-8 centigrade. This product is ... no mercury or azide. This formulation ...
384 Well PCR Plate Carrier for Thermo-Sealer...
Biology Products: